← Eichor
Study identifier: NCT04985032 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

Condition: Ductal Carcinoma in Situ · Invasive Ductal Carcinoma of Female Breast  ·  Sponsor: RPCR, Inc.

PhaseN/A
Planned participants200
Who can joinFemale, 50 Years to 100 Years
Healthy volunteersYes

About this study

This is a multi-institutional, prospective, observational registry investigating the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using a Stereotactic Body Radiation Therapy (SBRT) delivery technique that incorporates real-time image guidance, noncoplanar fields, and respiratory tracking. The study will accrue 200 patients who will be treated to a dose of 30 Gy over the course of 5 fractions. These subjects will then have a follow up time of 5 years

This description comes directly from the study's public registry record.

Talk to the study team

Mark Perman, MD  ·  772-293-0377  ·  Mark.Perman@usa.genesiscare.com

Debra Freeman, MD  ·  239-262-5168  ·  tbck.md@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

CyberKnife Center of South Florida in StuartStuart, Florida, United StatesRecruiting
CyberKnife Centers of Tampa BayTampa, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04985032